We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:11-20 of 5,704

Federal Court Ruling Provides Clarification for New Jersey Employers On Use of Medical Marijuana in the Workplace
  • Greenbaum, Rowe, Smith & Davis LLP
  • USA
  • August 10 2018

A recent opinion out of the United States District Court for the District of New Jersey provides New Jersey employers with some welcome insight into


Employers’ Prescription Drug Use Policies Coming Under Scrutiny
  • Hunton Andrews Kurth LLP
  • USA
  • August 9 2018

The opioid epidemic is causing employers to consider the best ways to ensure a safe workplace, but companies should be careful when addressing


CMS Releases Guidance Allowing Step Therapy for Part B Drugs
  • Cooley LLP
  • USA
  • August 7 2018

Today, the Centers for Medicare & Medicaid Services (CMS) released guidance and a Fact Sheet that will provide Medicare Advantage (MA) plans the


The Proposed Medicare OPPS Payment Rule: CMS Gets Tough on Site Neutral Payment
  • Morgan Lewis
  • USA
  • August 3 2018

Topping the list of significant policy changes are efforts by the Centers for Medicare & Medicaid Services (CMS) to expand site neutral reductions in


Disruptive innovation
  • Hill Dickinson LLP
  • USA, United Kingdom
  • August 3 2018

As the NHS has just celebrated its 70th Birthday, more and more of us will survive well beyond our own 70th birthdays. With medical advances meaning


It’s About More Than Hospitals: CY 2019 Proposed Hospital Outpatient Prospective Payment System Rule Contains Proposals of Interest to the Pharmaceutical Industry
  • Arent Fox LLP
  • USA
  • August 2 2018

Comments on the Proposed Rule are due back to the agency no later than September 24, 2018. Included with a host of proposals related to hospital


Publication Need not be IndexedSearchable to be Prior Art
  • Ropes & Gray LLP
  • USA
  • July 31 2018

Last week, I pointed out that the Federal Circuit faulted the Patent Trial & Appeal Board (PTAB) for its narrow public accessibility analysis in


PTAB Upholds GILENYA Method of Treatment Patent, Prompting New ANDA Litigation
  • Jones Day
  • USA
  • July 30 2018

In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not


CMS Responds to States’ Drug Pricing Proposals
  • Manatt Phelps & Phillips LLP
  • USA
  • July 30 2018

The Trump administration (the Administration) has called for a reduction in drug spending. In May, the Administration released a "blueprint" to


340B Update: CMS Proposes Changes to OPPS Reimbursement for Nonexcepted PBDs
  • K&L Gates
  • USA
  • July 30 2018

As part of the Calendar Year (“CY”) 2019 Medicare Outpatient Prospective Payment System (“OPPS”) Proposed Rule, the Centers for Medicare and Medicaid